Researchers are investigating a promising immune therapy that could significantly alter how depression is treated. Studies suggest that in some individuals, the immune system plays a role in the symptoms and severity of depression. A collaborative effort between psychiatrist Dr. James Murrough and dermatologist Dr. Emma Guttman-Yassky explored this link, initially surprising Dr. Murrough with the potential treatment outcomes.
Evidence has been mounting for decades that inflammation is implicated in depression. Individuals with inflammatory conditions like rheumatoid arthritis or skin diseases often exhibit higher rates of co-occurring depression. Stress, whether psychological or environmental, is also known to impact the immune system, potentially exacerbating depressive symptoms.
Dr. Guttman-Yassky's team compared inflammatory markers in patients with severe depression, psoriasis, and atopic dermatitis against healthy controls. Their findings indicated that the Th2 immune pathway is likely involved in depression, with its activity correlating to the severity of the condition. Notably, dupilumab, an antibody used for eczema and other inflammatory conditions, showed promise in preclinical models by potentially reversing immune signatures associated with depression.
This research highlights how inflammation can suppress the brain's response to reward, a key factor in depressive states. Functional brain imaging studies have shown a correlation between higher inflammatory markers and reduced responsiveness in the brain's reward centers. Conversely, inflammation may also heighten responses to threat, as seen in the amygdala. The researchers envision a future where a blood test could identify an immune dysfunction subtype of depression, allowing for personalized treatment with targeted therapies like dupilumab.